More importantly, HDAC2 inhibitors not only inhibit nuclear PD-L1 translocation, enhancing the efficacy of PD-1/PD-L1 checkpoint inhibitors, but also significantly increase the proportion of CD8+ and CD8+GranB (granzyme B)+ cells within tumor-infiltrating lymphocytes. Here, HDAC2 is linked to neoplasm.